Additive value of torsion to global longitudinal left ventricular strain in patients with reduced ejection fraction

Mornos, C.; Ruşinaru, Dan; Ionac, Adina; Petrescu, Lucian; Cozma, D.; Pescariu, S.; Dragulescu, Stefan I.

doi:10.1080/ac.66.5.2131080

Cited by 9 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There was no effect of the intervention on longitudinal strain, a consistent marker of subclinical cardiotoxicity [4], nor twist, which has also shown preliminary promise for prediction of cardiotoxicity [23,26,27]. Furthermore, in contrast to all previous observational studies of adults receiving anthracycline treatment [4,23], both parameters did not change over time.…”

Section: Discussionmentioning

confidence: 74%

The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT

Kirkham

Eves

Shave

et al. 2017

Breast Cancer Res Treat

107

View full text Add to dashboard Cite

An exercise bout performed 24 h prior to every doxorubicin treatment did not have an effect on markers of subclinical cardiotoxicity, but had a positive systemic effect on hemodynamics, musculoskeletal symptoms, mood, and body weight in women with breast cancer. A single exercise bout prior to chemotherapy treatments may be a simple clinical modality to reduce symptoms and weight gain among women with breast cancer.

show abstract

Section: Discussionmentioning

confidence: 74%

The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT

Kirkham

Eves

Shave

et al. 2017

Breast Cancer Res Treat

107

View full text Add to dashboard Cite

show abstract

“…Nine studies assessed the value of the relative change in GLS measured shortly after chemotherapy initiation compared with baseline (median [range] follow-up, 3 [2-6] months) . Most studies (7 of 9) used GE EchoPAC for GLS analysis.…”

Section: Resultsmentioning

confidence: 99%

“…20,22,27 Relative Change in GLS During Treatment Nine studies assessed the value of the relative change in GLS measured shortly after chemotherapy initiation compared with baseline (median [range] follow-up, 3 [2-6] months). 11,12,20,21,23,25,26,28,32 Most studies (7 of 9) used GE EchoPAC for GLS analysis. Among studies treating GLS as a continuous variable, the summary OR for the unadjusted association with subsequent CTRCD per 1% relative decrease in GLS was 1.19 (95% CI, 1.01-1.39), 25,28,32 whereas one study reported a significant association after multivariable adjustment for age, traditional cardiovascular risk factors, and LVEF (eTable 3 in the Supplement).…”

Section: Absolute Change In Gls During Treatmentmentioning

confidence: 99%

“…11,12,20,21,23,25,26,28,32 Most studies (7 of 9) used GE EchoPAC for GLS analysis. Among studies treating GLS as a continuous variable, the summary OR for the unadjusted association with subsequent CTRCD per 1% relative decrease in GLS was 1.19 (95% CI, 1.01-1.39), 25,28,32 whereas one study reported a significant association after multivariable adjustment for age, traditional cardiovascular risk factors, and LVEF (eTable 3 in the Supplement). 12 The univariate AUC for CTRCD in 6 studies ranged from 0.74 to 0.97 (median, 0.85).…”

Section: Absolute Change In Gls During Treatmentmentioning

confidence: 99%

“…12 The univariate AUC for CTRCD in 6 studies ranged from 0.74 to 0.97 (median, 0.85). 12,20,21,23,25,28 All 9 studies reported optimal cutoff values for relative change in GLS ranging from 2.3% to 15.9% (median, 13.7%), with a sensitivity and specificity between 45% and 100% (median, 86%) and 65% and 95% (median, 79%), respectively (Figure 1). Study-specific cutoff values were again independent of the reported sensitivity (ρ = 0.15; P = .71) and specificity (ρ = 0.11; P = .77).…”

Section: Absolute Change In Gls During Treatmentmentioning

confidence: 99%

See 2 more Smart Citations

Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity

et al. 2019

View full text Add to dashboard Cite

IMPORTANCE Echocardiographic left ventricular global longitudinal strain (GLS) detects early subclinical ventricular dysfunction and can be used in patients receiving potentially cardiotoxic chemotherapy. A meta-analysis of the prognostic value of GLS for cancer therapy-related cardiac dysfunction (CTRCD) has not been performed, to our knowledge. OBJECTIVE To explore the prognostic value of GLS for the prediction of CTRCD.DATA SOURCES Systematic search of the MEDLINE, Embase, Scopus, and the Cochrane Library databases from database inception to June 1, 2018.STUDY SELECTION Cohort studies assessing the prognostic or discriminatory performance of GLS before or during chemotherapy for subsequent CTRCD.DATA EXTRACTION AND SYNTHESIS Random-effects meta-analysis and hierarchical summary receiver operating characteristic curves (HSROCs) were used to summarize the prognostic and discriminatory performance of different GLS indices. Publication bias was assessed using the Egger test, and meta-regression was performed to assess sources of heterogeneity. MAIN OUTCOMES AND MEASURESThe primary outcome was CTRCD, defined as a clinically significant change in left ventricular ejection fraction with or without new-onset heart failure symptoms.RESULTS Analysis included 21 studies comprising 1782 patients with cancer, including breast cancer, hematologic malignancies, or sarcomas, treated with anthracyclines with or without trastuzumab. The incidence of CTRCD ranged from 9.3% to 43.8% over a mean follow-up of 4.2 to 23.0 months (pooled incidence, 21.0%). For active treatment absolute GLS (9 studies), the high-risk cutoff values ranged from −21.0% to −13.8%, with worse GLS associated with a higher CTRCD risk (odds ratio, 12.27; 95% CI,; area under the HSROC, 0.86; 95% CI, 0.83-0.89). For relative changes vs a baseline value (9 studies), cutoff values ranged from 2.3% to 15.9%, with a greater decrease linked to a 16-fold higher risk of CTRCD (odds ratio, 15.82; 95% CI, 5.84-42.85; area under the HSROC, 0.86; 95% CI, 0.83-0.89). Both indices showed significant publication bias. Meta-regression identified differences in sample size and CTRCD definition but not GLS cutoff value as significant sources of interstudy heterogeneity. CONCLUSIONS AND RELEVANCEIn this meta-analysis, measurement of GLS after initiation of potentially cardiotoxic chemotherapy with anthracyclines with or without trastuzumab had good prognostic performance for subsequent CTRCD. However, risk of bias in the original studies, publication bias, and limited data on the incremental value of GLS and its optimal cutoff values highlight the need for larger prospective multicenter studies.

show abstract

Associations between N-terminal pro-B-type natriuretic peptide and cardiac function in adults with corrected tetralogy of Fallot

Eindhoven¹,

Menting²,

Bosch³

et al. 2014

International Journal of Cardiology

View full text Add to dashboard Cite

Additive value of torsion to global longitudinal left ventricular strain in patients with reduced ejection fraction

Abstract: In patients with reduced LVEF, LVtor x LVE is a promising parameter that deserves research to establish its clinical meaning and prognostic value.

Cited by 9 publications

References 0 publications

The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT

The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT

Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity

Associations between N-terminal pro-B-type natriuretic peptide and cardiac function in adults with corrected tetralogy of Fallot

Contact Info

Product

Resources

About